Asked by: Adam Dance (Liberal Democrat - Yeovil)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what proportion of the NHS budget was allocated to primary care NHS dentistry excluding patient charge revenue in each financial year since 2010-11; and what estimate he has made of the proportion of the NHS budget that will be allocated to primary care NHS dentistry excluding patient charge revenue in each year from 2026-27 until 2029-30.
Answered by Stephen Kinnock - Minister of State (Department of Health and Social Care)
Prior to 2023/24 there was no specific dental budget allocation, as dentistry formed part of a wider budget which included community pharmacy and optometry. Since 2023/24, there has been a specific dental ringfence allocation for integrated care boards. This includes primary, secondary, and community dentistry and is set net of patient charges. The following table shows the dental budget as a proportion of the total National Health Service budget in each of the last two years:
Year | Proportion of NHS budget |
2023/24 | 2.17% |
2024/25 | 2.12% |
Note: the figure for 2025/2026 is not yet confirmed.
The details of budget allocations within each Government department for future years is still being determined. The Department is working to provide the detail and certainty needed on future funding and spending plans. This includes preparing for the first multi-year planning round for the NHS in more than half a decade, which will give local leaders the certainty they need to deliver.
Asked by: Adam Dance (Liberal Democrat - Yeovil)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, how much funding his Department plans to provide for NHS dentistry in each of the next three financial years.
Answered by Stephen Kinnock - Minister of State (Department of Health and Social Care)
Prior to 2023/24 there was no specific dental budget allocation, as dentistry formed part of a wider budget which included community pharmacy and optometry. Since 2023/24, there has been a specific dental ringfence allocation for integrated care boards. This includes primary, secondary, and community dentistry and is set net of patient charges. The following table shows the dental budget as a proportion of the total National Health Service budget in each of the last two years:
Year | Proportion of NHS budget |
2023/24 | 2.17% |
2024/25 | 2.12% |
Note: the figure for 2025/2026 is not yet confirmed.
The details of budget allocations within each Government department for future years is still being determined. The Department is working to provide the detail and certainty needed on future funding and spending plans. This includes preparing for the first multi-year planning round for the NHS in more than half a decade, which will give local leaders the certainty they need to deliver.
Asked by: Adam Dance (Liberal Democrat - Yeovil)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what recent discussions he has had with NHS dentists on rises in the costs for (a) NHS dental practices and (b) (i) laboratories and (ii) dental materials.
Answered by Stephen Kinnock - Minister of State (Department of Health and Social Care)
The Government is continuing to meet the British Dental Association and other representatives of the dental sector on a regular basis and some of these meetings have included the discussion of costs associated with delivering National Health Service dental care.
In addition, the Government is conducting a research project to better understand the costs and pressures associated with running a dental practice in England.
As part of this research, a survey was launched on 13 May 2025 and closed on 16 June 2025. This included questions on laboratory fees and dental materials as well as other associated costs with running a dental practice.
We are currently reviewing and analysing responses to understand findings.
Asked by: Adam Dance (Liberal Democrat - Yeovil)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what assessment the has made of the adequacy of the 1.68% uplift to the practice expenses element of the NHS dental contract in 2023-24, in the context of changes to the costs of running a dental practice.
Answered by Stephen Kinnock - Minister of State (Department of Health and Social Care)
The pay elements of the 2024/25 National Health Service contracts for general dental practitioners and salaried dentists were all uplifted by 6%, in line with the independent Review Body on Doctors’ and Dentists’ Remuneration’s recommendations. The overall contract value was uplifted by 4.64%, net of pay and expense elements. Uplifted payments were backdated to 1 April 2024.
Whilst no specific assessment of adequacy has been carried out, the use of a gross domestic product deflator for expenses was consistent with other areas across the NHS, including for general practitioners and ophthalmology.
Asked by: Adam Dance (Liberal Democrat - Yeovil)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what assessment he has made of the potential impact of the Ten Year Health Plan on community hospital bed provision in Yeovil constituency.
Answered by Stephen Kinnock - Minister of State (Department of Health and Social Care)
Our 10-Year Health Plan is creating a National Health Service truly fit for the future, keeping patients healthy and out of hospital, with care closer to home and in the home.
An impact statement for the plan will be published shortly.
Asked by: Adam Dance (Liberal Democrat - Yeovil)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what assessment he has made of the potential merits of prescribing medical cannabis as a treatment for the symptoms of attention deficit hyperactivity disorder.
Answered by Karin Smyth - Minister of State (Department of Health and Social Care)
No assessment has been made by the Department of the potential merits of prescribing medical cannabis as a treatment for symptoms of attention deficit hyperactivity disorder.
Where there are demonstrated therapeutic effects, we would expect manufactures to apply to the Medicines and Healthcare products Regulatory Agency (MHRA) for a marketing authorisation (licence) for their medicines, to enable prescribers to be confident of the medicine’s quality, safety and effectiveness.
Assessment by the National Institute for Health and Care Excellence (NICE) would then precede any routine prescribing on the NHS.
Asked by: Adam Dance (Liberal Democrat - Yeovil)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what assessment he has made of the potential merits of mandating digital prescribing for medical cannabis.
Answered by Karin Smyth - Minister of State (Department of Health and Social Care)
Cannabis-based products for medicinal use are Schedule 2 controlled drugs under the Misuse of Drugs Regulations 2001. Electronic prescribing of Schedule 2 and 3 Controlled Drugs in NHS primary care settings has been operational since 2019.
It is mandatory for electronic prescriptions for controlled drugs in Schedules 2 and 3 to be sent using an advanced electronic signature and sent via the NHS Electronic Prescribing Service as part of enhanced security measures.
There are no current plans to make legislative changes to enable similar systems in private healthcare to prescribe Schedule 2 and 3 controlled drugs.
Asked by: Adam Dance (Liberal Democrat - Yeovil)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, if he will implement the recommendations in Breast Cancer Now’s Setting the bar too high report in (a) Yeovil constituency and (b) the country.
Answered by Karin Smyth - Minister of State (Department of Health and Social Care)
The National Institute for Health and Care Excellence (NICE) makes recommendations on whether new medicines should be routinely funded by the National Health Service based on an assessment of their costs and benefits. NICE has processes in place to review its methods to ensure that they keep pace with best practice and are suitable for the evaluation of emerging new medicines.
NICE concluded a comprehensive review of the methods and processes it uses for health technology evaluations in January 2022, and introduced a number of changes that make its methods fairer, faster, and more consistent.
NICE’s board considered a review of the severity modifier at its public meeting on 25 September 2024, in light of its implementation to date, and concluded that it is operating as intended, so no change to the modifier is needed at the time.
NICE has no immediate plans to make further changes to its methods in response to the Breast Cancer Now report’s recommendations, but is monitoring the impact of the changes made following the methods review, and has committed to considering modular updates to its methods and processes in the future. NICE has also commissioned research to gather further evidence on societal preferences that will inform future methods reviews.
Asked by: Adam Dance (Liberal Democrat - Yeovil)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what discussions he has had with NICE on the impact of their severity modifier on people with secondary breast cancer in (a) Yeovil constituency and (b) the UK.
Answered by Karin Smyth - Minister of State (Department of Health and Social Care)
The Department has regular discussions with colleagues in the National Institute for Health and Care Excellence (NICE), including on the impact of the severity modifier on people with secondary breast cancer.
NICE carried out a review of the implementation of the severity modifier in September 2024 and found that it is operating as intended. This showed that the proportion of positive cancer recommendations is higher, at 84.8%, than with the end-of-life modifier it replaced, at 75%, and the proportion of positive recommendations for advanced cancer treatments is also higher, at 81.1% compared to 69%.
Since the introduction of the severity modifier, NICE has recommended all but one of the treatments for breast cancer that it has assessed. These treatments are now available to eligible National Health Service patients.
NICE has commissioned research to gather further evidence on societal preferences that will inform future method reviews.
Asked by: Adam Dance (Liberal Democrat - Yeovil)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what assessment he has made of the gender gap in neurodiversity diagnosis in (a) Yeovil constituency, (b) Somerset and (c) England.
Answered by Stephen Kinnock - Minister of State (Department of Health and Social Care)
We recognise that diagnosis rates of autism and attention deficit hyperactivity disorder (ADHD) are lower in women and girls and lower than the best evidence on prevalence. This may reflect differences in how autism and ADHD present in males and females, which may make these conditions more difficult to identify in women and girls.
Some information on autism and ADHD diagnosis rates by gender can be taken from the Health and Care of People with Learning Disabilities, Experimental Statistics 2023 to 2024, published by NHS England, and based on 54.7% of registered patients. This data shows that 0.82% of females have an autism diagnosis recorded on their general practice (GP) record, whereas for males it is 1.84%. For ADHD, 0.9% of women had an ADHD diagnosis on their GP record, compared to 1.6% of men.
National Institute for Health and Care Excellence guidelines on autism and ADHD set out considerations for clinicians when assessing for autism or ADHD, including highlighting that autism and ADHD may be under-recognised in women and girls.